Close

Make Kidney Cancer Treatment Priority- Kidney Cancer UK

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...
- Advertisement -

NICE, the National Institute for Health and Care Excellence, has received a plea from the Kidney Cancer UK to bring about guidelines on the diagnosis and treatment of kidney cancer as a significant priority.

Although NHS England has commissioned NICE to go through the urgent work, the recent results of a survey conducted by Kidney Cancer UK suggest that the policies have to be framed sooner rather than later.

The survey brings to light the fact that nearly a third of patients have waited for their turn in excess of three months, right from first presenting to a doctor to being given a proper diagnosis. Moreover, as per the survey, 22% of the patients were initially misdiagnosed.

The charity also highlights the need to ensure that kidney cancer is identified early and how it could be rectified by seamless guidelines, both on referrals as well as diagnosis.

The survey puts forth the fact that over 40% of the kidney cancer patients are still in the queue with three to five weeks left until their scan results. The survey, surprisingly, also brings up the fact that 48% of kidney cancer in patients was discovered incidentally through a scan that was not predominantly done for that.

It is well to noted that patients were unhappy with the fact that when the diagnosis was made, the method used to share the result with them was uncalled forโ€”it was often done over the phone.

The University of Cambridgeโ€™s Professor Grant Stewart stated in his analysis that the nature of the statistics in this survey has been deeply concerning because these diagnoses and services are occurring post-COVID-19. The fact that 40% of the patients are diagnosed at stage 3 or stage 4 downplays the NHS’s long-term plan of diagnosing three out of four cancers at stage 1 or stage 2 by 2028.

Associate Professor of Radiology from the University Hospital of Southampton, Dr. David Breen opines that one needs to get into less invasive and more effective treatments like Cryoablation when it comes to sub 4-5cms kidney tumours. This surely reflects the need of the patient and significantly spares the kidney function in the background. Although ablation might not be perfect for all kidney cancer patients, it must be discussed in the case of smaller kidney cancers.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...

WHO Introduces Global Regulatory Framework for Decarbonizing Pharmaceuticals

The World Health Organization (WHO) has officially launched the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป